Clinical Trials Logo

Gastroparesis clinical trials

View clinical trials related to Gastroparesis.

Filter by:

NCT ID: NCT01191138 Completed - Clinical trials for Postprocedural Gastric Stasis

Gastric Emptying After Infracolic or Supracolic Gastrojejunostomy Following Pancreaticoduodenectomy

Start date: January 2009
Phase: N/A
Study type: Interventional

Patients undergoing whipples pancreaticoduodenectomy tend to develop delayed gastric emptying. The study compares two types of anastamosis of stomach to jejunum (supracolic and infracolic) and compares whether it influences the gastric emptying. The clinical evidence of delayed gastric emptying is correlated with objective evidence of liquid and solid emptying by radionuclide study. The study also tries to evaluate whether pancreatic leak correlates with delayed gastric emptying

NCT ID: NCT01173484 Terminated - Gastroparesis Clinical Trials

Idiopathic Gastroparesis Registry Using a Predominant-Symptom Classification

Start date: June 2010
Phase: N/A
Study type: Observational

The diagnosis of "gastroparesis" suggests that delayed gastric emptying is the underlying cause of symptoms, but this description fails to explain the variable presentation. There are fundamental differences in causes, symptoms, and prognosis among patients with idiopathic gastroparesis. Understanding these differences is necessary in order to provide effective treatment in these patients. We believe our classification for gastroparesis is a useful tool in the management of patients with idiopathic gastroparesis to predict clinical severity, treatment response, and future prognosis.

NCT ID: NCT01149369 Completed - Gastroparesis Clinical Trials

Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial

APRON
Start date: April 2013
Phase: Phase 2
Study type: Interventional

The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether 4 weeks of treatment with aprepitant will improve nausea as compared with placebo in patients with symptoms of chronic nausea and vomiting of presumed gastric origin.

NCT ID: NCT01135186 Completed - Gastroparesis Clinical Trials

Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.

Start date: May 2010
Phase: N/A
Study type: Interventional

Kuvan® (sapropterin dihydrochloride) for Improving Gastric Accommodation in Women with Diabetic Gastroparesis (KIGA-DG)

NCT ID: NCT01126034 Completed - Clinical trials for Gastroesophageal Reflux Disease

Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention

Start date: March 2007
Phase: N/A
Study type: Interventional

The investigators hypothesized that: 1) an intervention targeted at the prescribing physician would increase the rate of a metoclopramide discontinuation among patients prescribed the medication for questionable or unclear indications; and 2) the discontinuation would be durable.

NCT ID: NCT01117376 Terminated - Gastroparesis Clinical Trials

Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients

Start date: May 2010
Phase: Phase 2
Study type: Interventional

42 patients admitted in ICU with intolerance to enteral feeding (GRV more than 250 ml) are recruited. All patients enter a primary acetaminophen absorption test study as baseline. Serum levels of acetaminophen will be measured by florescence polarization method at 15,30,45,60,90,120,180,240,480 minutes after enteral administration of 975 mg acetaminophen. Then the patients will be randomized to methylnaltrexone or erythromycin group.Another acetaminophen absorption test with the same schedule will be done after the last dose of each drug.The area under the curve for acetaminophen blood level will be used to compare the effect of two studied drugs on gastric emptying time.

NCT ID: NCT01074710 Completed - Gastroparesis Clinical Trials

Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers

Start date: February 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and establish the pharmacokinetic (PK) profile of C13-URA in healthy volunteers

NCT ID: NCT01054794 Completed - Gastroparesis Clinical Trials

Temporary Gastric Electrical Stimulation for Gastroparesis

Start date: December 2009
Phase: N/A
Study type: Interventional

This is a prospective study of temporary gastric mucosal electrical stimulation (tGES) in 30 patients with gastroparesis (GP). After a 7 day baseline assessment of symptoms, subjects will have an endoscopically-placed tGES lead implanted into the mucosa of the antrum. This lead is connected to a thin wire that runs up the esophagus and out the nostril, similar to a nasojejunal feeding tube, although much thinner. It is then attached to a programmable battery pack which provides the desired level of stimulation. Patients will then be randomized to 7 days OFF or 7 days ON stimulation in a double-blind fashion. After 7 days, subjects will crossover to the other study arm (ie ON patients will be switched off; OFF patients will be switched on). Symptoms and QoL measures will be assessed at baseline, ON, and OFF periods. Serum ghrelin and other hormones, as well as EGG will be assayed after 6 days in each arm.

NCT ID: NCT01039974 Completed - Gastroparesis Clinical Trials

GSK962040 Drug-drug Interaction Study With Ketoconazole

Start date: September 18, 2009
Phase: Phase 1
Study type: Interventional

This study will determine the effect of 400 mg ketoconazole on the pharmacokinetics of a single dose of GSK962040. The results from this study will help to estimate the maximum increase in exposure during concomitant use of strong CYP3A4 inhibitors. This study will also contain an exploratory investigation of biliary secretion of GSK962040 and or its metabolites.

NCT ID: NCT01039805 Completed - Gastroparesis Clinical Trials

Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance

Start date: December 2009
Phase: Phase 2
Study type: Interventional

The aims of MOT112571 are to assess the pharmacodynamic effects, safety, tolerability, pharmacokinetics, and potential therapeutic benefit of single doses of GSK962040 in critically ill patients with delayed gastric emptying and who are intolerant to enteral feeding.